Dermatological adverse effects of doxycycline as post-exposure prophylaxis for sexually transmitted infections among men who have sex with men: real-world findings from a multicentre study
作者:Ling-Ya Chen, Wei-Ting Lin, Yi‐Ting Chen, Po-Hsien Kuo, Wang-Da Liu, Yu‐Shan Huang, Hsin‐Yun Sun, Aristine Cheng, Yu‐Zhen Luo, Pei‐Ying Wu, Hsi‐Yen Chang, Kuan‐Yin Lin, Chien‐Ching Hung · 发表于:Journal of Antimicrobial Chemotherapy · 年份:2025 · DOI:10.1093/jac/dkaf351 · 被引用次数:2 · 研究领域:Drug-Induced Adverse Reactions、Contact Dermatitis and Allergies、HIV/AIDS Research and Interventions
OBJECTIVES: Doxycycline has demonstrated a favourable safety profile in clinical trials of post-exposure prophylaxis (doxy-PEP) for sexually transmitted infections; however, potential adverse effects may limit its feasibility. We aimed to investigate dermatological adverse effects of doxy-PEP in real-world settings. METHODS: This multicentre retrospective cohort study was conducted between October 2023 and February 2025, following the implementation of doxy-PEP among MSM. Individuals were encouraged to report adverse effects after initiating doxy-PEP. Data on medical history, previous therapeutic doxycycline exposure and history of allergic reactions were collected from electronic medical records. RESULTS: A total of 671 MSM were included, comprising 460 people with HIV and 211 on pre-exposure prophylaxis. Among them, nine individuals (1.3%) developed skin reactions, with an incidence rate of 1.0 per 100 person-years. Most were fixed drug eruptions (n = 8), with one case of photosensitivity. These reactions typically appeared within 24 h of exposure; and all nine individuals discontinued doxy-PEP, and symptoms resolved within 1-3 weeks. Individuals with a prior history of allergic reactions to any medication were at greater risk of experiencing adverse skin reactions (odds ratio, 6.99; 95% CI, 1.83-26.65). Notably, all individuals who experienced dermatological adverse events had previously used therapeutic doxycycline, though only three reported prior allergic reactions to i...